Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Ivelina, Gueorguieva"'
Autor:
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolu
Externí odkaz:
https://doaj.org/article/f152b1db103e441ba5117026cc7aba88
Autor:
Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest II, Jian Wang, Sergey Shcherbinin, John R. Sims, Emmanuel Chigutsa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 2, Pp n/a-n/a (2023)
Abstract INTRODUCTION Donanemab is an amyloid‐targeting therapy that specifically targets brain amyloid plaques. The objective of these analyses was to characterize the relationship of donanemab exposure with plasma biomarkers and clinical efficacy
Externí odkaz:
https://doaj.org/article/46f199eccdf94cd1a9b67b5c825effb4
Autor:
James J. Harding, Richard K. Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Robin K. Kelley, Ghassan K. Abou‐Alfa
Publikováno v:
Cancer Medicine, Vol 10, Iss 9, Pp 3059-3067 (2021)
Abstract Background Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of b
Externí odkaz:
https://doaj.org/article/a3e937bb75b74d4cbd5609cb1c0768da
Autor:
Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, John R. Sims
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1258-1267
Autor:
Antoine Hollebecque, Rocio Garcia-Carbonero, Do-Youn Oh, Emiliano Calvo, Davide Melisi, Teresa Macarulla, Valeria Merz, Erkut Borazanci, Anna Varghese, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T Estrem, Karim A Benhadji, Emin Avsar, Susan C Guba
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refracto
Externí odkaz:
https://doaj.org/article/c175cf79b75445f3ae95a488c7252728
Autor:
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon
Publikováno v:
Drugs in Context, Pp 1-8 (2016)
Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to
Externí odkaz:
https://doaj.org/article/93831356d0004c618b43eff7688ea65b
Autor:
Amit Verma, Britta Will, Ashwin Sridharan, Ulrich Steidl, Kith Pradhan, Tushar D. Bhagat, Mariana da Silva Ferreira, Allicia C. Girvan, Ivelina Gueorguieva, Susan C. Guba, Aristoteles Giagounidis, Alan Chiang, Yumin Zhao, Jan Janssen, Michael M. Lahn, Ann L. Cleverly, Rami S. Komrokji, Uwe Platzbecker, David Valcárcel, Valeria Santini
Purpose:Overactivation of TGF-β signaling is observed in myelodysplastic syndromes (MDS) and is associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor of the TGF-β receptor type 1 kinase (ALK5) has s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb4bf8b859cd1520d1aa31144a1567c6
https://doi.org/10.1158/1078-0432.c.6528228
https://doi.org/10.1158/1078-0432.c.6528228
Autor:
Jose Baselga, Michael M. Lahn, Jaishri Blakeley, Matthias Holdhoff, Luis Paz-Ares, Shawn T. Estrem, Durisala Desaiah, N. Sokalingum Pillay, Ann L. Cleverly, Ivelina Gueorguieva, Elisabet Sicart, Irene Braña, Joan Seoane, Emiliano Calvo, Analia Azaro, Juan M Sepulveda-Sánchez, Michael A. Carducci, Jordi Rodon
Legend for Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51c1c1f4ed28eec64cdd79e5551d37d
https://doi.org/10.1158/1078-0432.22456181
https://doi.org/10.1158/1078-0432.22456181
Autor:
Jose Baselga, Michael M. Lahn, Jaishri Blakeley, Matthias Holdhoff, Luis Paz-Ares, Shawn T. Estrem, Durisala Desaiah, N. Sokalingum Pillay, Ann L. Cleverly, Ivelina Gueorguieva, Elisabet Sicart, Irene Braña, Joan Seoane, Emiliano Calvo, Analia Azaro, Juan M Sepulveda-Sánchez, Michael A. Carducci, Jordi Rodon
Purpose: TGFβ signaling plays a key role in tumor progression, including malignant glioma. Small-molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGFβ signaling and reduce tumor progression in preclinical models. To use LY2157299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d6dd8ca21d315c487ee240d4f784d86
https://doi.org/10.1158/1078-0432.c.6523229
https://doi.org/10.1158/1078-0432.c.6523229
Autor:
Jose Baselga, Michael M. Lahn, Jaishri Blakeley, Matthias Holdhoff, Luis Paz-Ares, Shawn T. Estrem, Durisala Desaiah, N. Sokalingum Pillay, Ann L. Cleverly, Ivelina Gueorguieva, Elisabet Sicart, Irene Braña, Joan Seoane, Emiliano Calvo, Analia Azaro, Juan M Sepulveda-Sánchez, Michael A. Carducci, Jordi Rodon
Supplemental Figure 1. Platelet recovery after lomustine administration was not diminished by giving LY2157299 during the recovery period suggesting no bone marrow toxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ac65a2119252817a49081673357db3
https://doi.org/10.1158/1078-0432.22456178.v1
https://doi.org/10.1158/1078-0432.22456178.v1